Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia

Hypertension

Volumn 70, Issue 2, 2017, Pages 382-389

  Stanhewicz, Anna E ^a   Jandu, Sandeep ^b   Santhanam, Lakshmi ^b   Alexander, Lacy M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin II; endothelium; losartan; microvessels; preeclampsia

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G) NITROARGININE METHYL ESTER; UREA; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CONDUCTANCE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; FEMALE; HEATING; HUMAN; HUMAN TISSUE; MEAN ARTERIAL PRESSURE; MICROVASCULATURE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; UREA NITROGEN BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; DRUG EFFECTS; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY;

ADULT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MICROVESSELS; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 2; VASODILATION;

EID: 85021298167     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.09386     Document Type: Article

References (60)

1. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation. 2011;123:1243-1262. doi: 10.1161/CIR.0b013e31820faaf8.
2. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011;7:467-474. doi: 10.2147/VHRM.S20181.
3. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974. doi: 10.1136/bmj.39335.385301.BE.
4. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166-171. doi: 10.1161/HYPERTENSIONAHA.110.150078.
5. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol. 2014;63:1815-1822. doi: 10.1016/j.jacc.2014.02.529.
6. Haukkamaa L, Salminen M, Laivuori H, Leinonen H, Hiilesmaa V, Kaaja R. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol. 2004;93:805-808. doi: 10.1016/j.amjcard.2003.11.065.
7. Ghossein-Doha C, van Neer J, Wissink B, Breetveld NM, de Windt LJ, van Dijk AP, van der Vlugt MJ, Janssen MC, Heidema WM, Scholten RR, Spaanderman ME. Pre-eclampsia: an important risk factor for asymptomatic heart failure. Ultrasound Obstet Gynecol. 2017;49:143-149. doi: 10.1002/uog.17343.
8. Jónsdóttir LS, Arngrímsson R, Geirsson RT, Sigvaldason H, Sigfússon N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand. 1995;74:772-776.
9. Arnadottir GA, Geirsson RT, Arngrimsson R, Jonsdottir LS, Olafsson O. Cardiovascular death in women who had hypertension in pregnancy: a case-control study. BJOG. 2005;112:286-292. doi: 10.1111/j.1471-0528.2004.00396.x.
10. Alvarez-Alvarez B, Martell-Claros N, Abad-Cardiel M, García-Donaire JA. [Hypertensive disorders during pregnancy: cardiovascular longterm outcomes]. Hipertens Riesgo Vasc. 2017;34:85-92. doi: 10.1016/j. hipert.2016.06.002.
11. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001;285:1607-1612.
12. Hausvater A, Giannone T, Sandoval YH, Doonan RJ, Antonopoulos CN, Matsoukis IL, Petridou ET, Daskalopoulou SS. The association between preeclampsia and arterial stiffness. J Hypertens. 2012;30:17-33. doi: 10.1097/HJH.0b013e32834e4b0f.
13. Evans CS, Gooch L, Flotta D, Lykins D, Powers RW, Landsittel D, Roberts JM, Shroff SG. Cardiovascular system during the postpartum state in women with a history of preeclampsia. Hypertension. 2011;58:57-62. doi: 10.1161/HYPERTENSIONAHA.111.173278.
14. Orabona R, Sciatti E, Vizzardi E, Bonadei I, Valcamonico A, Metra M, Frusca T. Endothelial dysfunction and vascular stiffness in women with previous pregnancy complicated by early or late pre-eclampsia. Ultrasound Obstet Gynecol. 2017;49:116-123. doi: 10.1002/uog.15893.
15. Hamad RR, Eriksson MJ, Silveira A, Hamsten A, Bremme K. Decreased flow-mediated dilation is present 1 year after a pre-eclamptic pregnancy. J Hypertens. 2007;25:2301-2307. doi: 10.1097/HJH.0b013e3282ef5fc0.
16. Cunningham MW Jr, Williams JM, Amaral L, Usry N, Wallukat G, Dechend R, LaMarca B. Agonistic autoantibodies to the angiotensin II type 1 receptor enhance angiotensin II-induced renal vascular sensitivity and reduce renal function during pregnancy. Hypertension. 2016;68:1308-1313. doi: 10.1161/HYPERTENSIONAHA.116.07971.
17. Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension. 2011;58:77-84. doi: 10.1161/HYPERTENSIONAHA. 111.171348.
18. Dekker GA, Makovitz JW, Wallenburg HC. Prediction of pregnancyinduced hypertensive disorders by angiotensin II sensitivity and supine pressor test. Br J Obstet Gynaecol. 1990;97:817-821.
19. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973;52:2682-2689. doi: 10.1172/JCI107462.
20. Whalley PJ, Everett RB, Gant NF, Cox K, MacDonald PC. Pressor responsiveness to angiotensin II in hospitalized primigravid women with pregnancy-induced hypertension. Am J Obstet Gynecol. 1983;145: 481-483.
21. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945-952. doi: 10.1172/JCI4106.
22. Wallukat G, Neichel D, Nissen E, Homuth V, Luft FC. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can J Physiol Pharmacol. 2003;81:79-83. doi: 10.1139/ y02-160.
23. Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, Seely EW. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension. 2010;55:1239-1245. doi: 10.1161/HYPERTENSIONAHA.109.147595.
24. Walther G, Obert P, Dutheil F, Chapier R, Lesourd B, Naughton G, Courteix D, Vinet A. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: crosssectional study. Arterioscler Thromb Vasc Biol. 2015;35:1022-1029. doi: 10.1161/ATVBAHA.114.304591.
25. Holowatz LA, Thompson-Torgerson CS, Kenney WL. The human cutaneous circulation as a model of generalized microvascular function. J Appl Physiol. 2008;105:370-372. doi: 10.1152/japplphysiol.00858.2007.
26. Kenney WL, Cannon JG, Alexander LM. Cutaneous microvascular dysfunction correlates with serum LDL and slox-1 receptor concentrations. Microvasc Res. 2013;85:112-117. doi: 10.1016/j.mvr.2012.10.010.
27. Khan F, Patterson D, Belch JJ, Hirata K, Lang CC. Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography. Clin Sci (Lond). 2008;115:295-300. doi: 10.1042/CS20070431.
28. Coulon P, Constans J, Gosse P. Impairment of skin blood flow during postocclusive reactive hyperhemy assessed by laser Doppler flowmetry correlates with renal resistive index. J Hum Hypertens. 2012;26:56-63. doi: 10.1038/jhh.2010.117.
29. Debbabi H, Bonnin P, Ducluzeau PH, Lefthériotis G, Levy BI. Noninvasive assessment of endothelial function in the skin microcirculation. Am J Hypertens. 2010;23:541-546. doi: 10.1038/ajh.2010.10.
30. ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American college of obstetricians and gynecologists. International J Gynaecol Obstet 2002;77:67-75.
31. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
32. Bruning RS, Santhanam L, Stanhewicz AE, Smith CJ, Berkowitz DE, Kenney WL, Holowatz LA. Endothelial nitric oxide synthase mediates cutaneous vasodilation during local heating and is attenuated in middleaged human skin. J Appl Physiol. 2012;112:2019-2026. doi: 10.1152/ japplphysiol.01354.2011.
33. Stewart JM, Taneja I, Glover J, Medow MS. Angiotensin II type 1 receptor blockade corrects cutaneous nitric oxide deficit in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. 2008;294:H466-H473. doi: 10.1152/ajpheart.01139.2007.
34. Johnson JM, O'Leary DS, Taylor WF, Kosiba W. Effect of local warming on forearm reactive hyperaemia. Clin Physiol. 1986;6:337-346.
35. Smith CJ, Santhanam L, Bruning RS, Stanhewicz A, Berkowitz DE, Holowatz LA. Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans. Hypertension. 2011;58:935-942. doi: 10.1161/ HYPERTENSIONAHA.111.178129.
36. Minson CT, Berry LT, Joyner MJ. Nitric oxide and neurally mediated regulation of skin blood flow during local heating. J Appl Physiol (1985). 2001;91:1619-1626.
37. Minson CT. Thermal provocation to evaluate microvascular reactivity in human skin. J Appl Physiol. 2010;109:1239-1246. doi: 10.1152/ japplphysiol.00414.2010.
38. Wenner MM, Wilson TE, Davis SL, Stachenfeld NS. Pharmacological curve fitting to analyze cutaneous adrenergic responses. J Appl Physiol (1985). 2011;111:1703-1709. doi: 10.1152/japplphysiol.00780.2011.
39. Scholten RR, Spaanderman ME, Green DJ, Hopman MT, Thijssen DH. Retrograde shear rate in formerly preeclamptic and healthy women before and after exercise training: relationship with endothelial function. Am J Physiol Heart Circ Physiol. 2014;307:H418-H425. doi: 10.1152/ ajpheart.00128.2014.
40. Fuchs D, Dupon PP, Schaap LA, Draijer R. The association between diabetes and dermal microvascular dysfunction non-invasively assessed by laser doppler with local thermal hyperemia: a systematic review with meta-analysis. Cardiovascular Diabetology. 2017;16:11. doi: 10.1186/ s12933-016-0487-1.
41. Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecologica. 2010;62:105-120.
42. Hladunewich MA, Kingdom J, Odutayo A, Burns K, Lai V, O'Brien T, Gandhi S, Zimpelmann J, Kiss A, Miller J, Cherney D. Postpartum assessment of the renin angiotensin system in women with previous severe, early-onset preeclampsia. J Clin Endocrinol Metab. 2011;96:3517-3524. doi: 10.1210/jc.2011-1125.
43. Brewer J, Liu R, Lu Y, Scott J, Wallace K, Wallukat G, Moseley J, Herse F, Dechend R, Martin JN Jr, Lamarca B. Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension. 2013;62:886-892. doi: 10.1161/ HYPERTENSIONAHA.113.01648.
44. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, Markovic N, Thadhani R, Luft FC, Dechend R. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension. 2007;49:612-617. doi: 10.1161/01. HYP.0000256565.20983.d4.
45. Yang X, Wang F, Chang H, Zhang S, Yang L, Wang X, Cheng X, Zhang M, Ma XL, Liu H. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens. 2008;26:1629-1635. doi: 10.1097/ HJH.0b013e328304dbff.
46. Orabona R, Sciatti E, Vizzardi E, Bonadei I, Prefumo F, Valcamonico A, Metra M, Frusca T. Maternal endothelial function and vascular stiffness after HELLP syndrome: A case-control study [published online ahead of print December 22, 2016]. Ultrasound Obstet Gynecol. doi: 10.1002/ uog.17394. http://onlinelibrary.wiley.com/doi/10.1002/uog.17394/full. Accessed January 4, 2017.
47. Weissgerber TL, Milic NM, Milin-Lazovic JS, Garovic VD. Impaired flow-mediated dilation before, during, and after preeclampsia: a systematic review and meta-analysis. Hypertension. 2016;67:415-423. doi: 10.1161/HYPERTENSIONAHA.115.06554.
48. Henriques AC, Carvalho FH, Feitosa HN, Macena RH, Mota RM, Alencar JC. Endothelial dysfunction after pregnancy-induced hypertension. Int J Gynaecol Obstet. 2014;124:230-234. doi: 10.1016/j.ijgo.2013.08.016.
49. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol. 2007;152:1042-1048. doi: 10.1038/sj.bjp.0707454.
50. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372-1378.
51. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869. doi: 10.1056/NEJMoa011161.
52. Mason RP. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2011;7:405-416. doi: 10.2147/VHRM.S20737.
53. Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360. doi: 10.1155/2014/689360.
54. Cheetham C, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci (Lond). 2001;100:13-17.
55. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol. 2000;36:1461-1466.
56. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5:301-314.
57. Committee opinion no. 638: first-trimester risk assessment for earlyonset preeclampsia. Obstet Gynecol. 2015;126:e25-27. doi: 10.1097/ AOG.0000000000001049.
58. Spradley FT. Metabolic abnormalities and obesity's impact on the risk for developing preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2017;312:R5-R12. doi: 10.1152/ajpregu.00440.2016.
59. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. Am J Epidemiol. 2014;180:346-358. doi: 10.1093/aje/kwu145.
60. Stickford AS, Okada Y, Best SA, Parker RS, Levine BD, Fu Q. Sympathetic neural and cardiovascular responses during static handgrip exercise in women with a history of hypertensive pregnancy. Clin Auton Res. 2016;26:395-405. doi: 10.1007/s10286-016-0372-8.